Welcome to our dedicated page for Sanuwave Health SEC filings (Ticker: SNWV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Sanuwave Health, Inc. (SNWV) SEC filings page on Stock Titan provides access to the company’s U.S. Securities and Exchange Commission disclosures, including current reports on Form 8-K, proxy statements, and other regulatory documents. Sanuwave is a Nevada corporation whose common stock trades on NASDAQ under the symbol SNWV, and its filings offer detailed information on operations, governance, and financing.
Recent Forms 8-K describe results of operations and financial condition for specific quarters, including press releases announcing revenue, gross margin, operating income, and non-GAAP metrics such as EBITDA and Adjusted EBITDA. Other 8-K filings cover material definitive agreements, such as a secured credit facility with JPMorgan Chase Bank, N.A. that includes a term loan and revolving credit facility, and the termination of a prior debt facility with NH Expansion Credit Fund Holdings LP.
Additional 8-K items document corporate actions and governance events, including changes in executive officers, separation and release agreements, stockholder meeting results, and amendments to the 2024 Equity Incentive Plan. One filing also describes a license and option agreement related to intravascular shockwave patents and the subsequent exercise of the option by the licensee, resulting in a cash payment to Sanuwave.
Investors interested in capital structure and shareholder matters can review the company’s definitive proxy statement (DEF 14A), which discusses director elections, ratification of the independent registered public accounting firm, advisory votes on executive compensation, and details of the reverse stock split of Sanuwave’s common stock.
On Stock Titan, these filings are updated from the SEC’s EDGAR system, and AI-powered tools can help summarize key points, highlight significant items in Forms 8-K, and clarify the implications of proxy proposals and financing agreements. This allows readers to quickly understand how Sanuwave’s regulatory disclosures relate to its advanced wound care and regenerative medicine business.
Opaleye Management Inc., a more than 10% owner of SANUWAVE Health, Inc., reported open-market sales of the company’s common stock over two days. On April 28, 2026, accounts it manages sold 46,288 shares at a weighted average price of $18.4674 per share, in multiple trades between $18.41 and $18.6615.
On April 29, 2026, these accounts sold an additional 24,360 shares at a weighted average price of $17.2476, in trades between $16.58 and $17.51. After the transactions, Opaleye-related vehicles held 887,650 shares through Opaleye, L.P. and 6,500 shares in a separately managed account, and Opaleye Management disclaims beneficial ownership beyond its pecuniary interest.
SANUWAVE Health, Inc. has called a virtual annual stockholder meeting for June 11, 2026, asking investors to vote on board elections, auditor ratification, and executive pay. Stockholders will elect five directors, including CEO and chairman Morgan Frank, to serve until the 2027 meeting.
Investors are also asked to ratify Baker Tilly US, LLP as independent auditor for 2026 and to approve, on a non-binding basis, compensation for named executive officers. The board highlights that four of five directors are independent and that it uses a lead independent director and fully independent audit, compensation, and nominating committees.
The proxy describes a Nasdaq-compliant clawback policy adopted in March 2025 and explains that, although prior periods were restated, no incentive-based compensation was received in the affected years, so no recovery was required. It also outlines equity incentive plans, option grants, related-party financings previously converted into equity, and current ownership levels of major shareholders and insiders.
Opaleye-related entities reported open-market sales of SANUWAVE Health, Inc. common stock. On April 17, Opaleye, L.P. sold 11,267 shares at a weighted average price of $20.4611 per share, and a separately managed account sold 5,000 shares at the same price.
On April 21, Opaleye, L.P. sold an additional 202 shares at a weighted average price of $20.5025. Following these transactions, Opaleye, L.P. held 954,798 shares, and the managed account held 10,000 shares. Opaleye Management Inc. disclaims beneficial ownership beyond its pecuniary interest.
Sanuwave Health, Inc. reported preliminary revenue for the quarter ended March 31, 2026 of $9.6–$9.7 million, an increase of 3–4% over the same quarter in 2025 and in line with its prior Q1 guidance.
Management noted that several larger deals slipped out of the quarter but remain active, contributing to results landing toward the lower end of the guided range. The company highlighted disruption in advanced wound care from reimbursement changes for skin substitutes and allografts, which has caused some customers to pause or scale back activity.
Sanuwave described strong practitioner interest in its Ultramist technology at a recent wound care conference and indicated it plans to “lean in” to the market rather than pull back. The company emphasized that these figures are preliminary and may change when full Q1 results are reported in May.
SANUWAVE Health, Inc. director Tyler James reported receiving a grant of stock options. The award covers 3,208 options, each giving the right to buy one share of common stock at an exercise price of $17.29 per share. According to the filing, these options were fully vested on the grant date and expire on March 31, 2031. Following this grant, James holds 3,208 stock options directly, with no common stock purchases or sales reported in this filing.
SANUWAVE Health, Inc. reported that Chief Executive Officer Frank C. Morgan received a grant of stock options. He was awarded options to purchase 3,208 shares of common stock at an exercise price of $17.29 per share, fully vested on the grant date. These options expire on March 31, 2031, and following this grant he holds 3,208 stock options directly.
SANUWAVE Health, Inc. director Jeffrey Blizard reported a grant of stock options as part of his compensation. On March 31, 2026, he acquired 3,208 stock options, each giving the right to buy one share of common stock at an exercise price of $17.29.
The options were fully vested at the grant date and expire on March 31, 2031. Following this grant, Blizard holds 3,208 derivative securities directly, reflecting a routine award rather than an open-market purchase or sale.
SANUWAVE Health director Gregory Matthew Bazar received a grant of stock options covering 3,208 shares of Common Stock. The options have an exercise price of $17.29 per share and were fully vested on the grant date.
The options expire on March 31, 2031, and give him the right to buy up to 3,208 shares if exercised.
SANUWAVE Health, Inc. director Ian D. Miller received a grant of stock options covering 3,609 shares of common stock. The options have an exercise price of $17.29 per share, were fully vested on the grant date, and expire on March 31, 2031. Following this compensation award, Miller holds 3,609 derivative securities directly, with no related share sales or open-market purchases reported in this filing.